Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

Summary

Research by Spherix shows that nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring hemophilia A patients for gene therapy, reflecting higher standards amid recent market contraction, though patient interest in the modality remains.